Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
NCT00006812Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Mar 2001
- Primary completion
- Jul 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in ovarian cancer and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Primary endpoints: Antitumor activity and Nature and degree of toxicity. Started Mar 2001; status: terminated.
02
Drugs
capecitabine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00006812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006812.